Anti-sheep interleukin-6 antibody, antibody pair and application thereof
By providing high affinity and specific antibodies, the problem of low detection sensitivity of IL-6 in the prior art is solved, and high accuracy and high sensitivity of sheep IL-6 detection is achieved, which promotes disease prevention and monitoring in the sheep breeding industry.
Patent Information
- Application Number
- CN202410839173.6
- Authority / Receiving Office
- CN · China
- Patent Type
- Patents(China)
- Current Assignee / Owner
- Filing Date
- 2024-06-26
- Publication Date
- 2024-11-26
- Estimated Expiration
- 2044-06-26
AI Technical Summary
The lack of high affinity and specific antibodies in the prior art leads to low sensitivity for immunoassays for IL-6, making it difficult to accurately detect the expression level of IL-6 in sheep blood, affecting disease prevention and monitoring.
Two rabbit-derived antibodies and their antibody pairs are provided, with high recognition specificity and binding activity, and are used to develop high-sensitivity IL-6 detection methods, including a dual-anti-sandwich method enzyme-linked immunosorbent assay detection system.
It realizes high accuracy, specificity and sensitivity detection of goat IL-6 protein, provides excellent antibody raw materials, and can quantitatively detect trace IL-6 in serum, cell and tissue samples, with broad market prospects and Good economic and social benefits.
Smart Images

Figure CN118561998B_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of immunological detection, and in particular to an anti-sheep interleukin 6 antibody, an antibody pair and applications thereof. Background Art
[0002] Interleukin-6 (IL-6), referred to as interleukin 6 or IL6, belongs to the interleukin family. It is a multifunctional cellular inflammatory factor with a wide range of functions. It is mainly produced in fibroblasts, monocytes / macrophages, T cells, B cells, epithelial cells, keratinocytes and various tumor cells. IL-6 can regulate the growth and differentiation of various cells, induce B cell differentiation to produce immunoglobulins, promote the proliferation and growth of T cells, promote the proliferation of bone marrow hematopoietic stem cells, and enhance the differentiation of blood cells and their anti-tumor effects. It has the function of regulating immune response, acute phase response and hematopoietic function, and plays an important role in the body's anti-infection immune response. IL-6 is an important cytokine expressed by the innate immune system in the initial response to injury and infection. It can promote the liver to produce acute phase reactants (such as CRP, PCT, C3, SAA, etc.). It is a sensitive indicator for the early diagnosis of acute infection. Its serum concentration level increases earlier than PCT and CRP. It can be used for early warning diagnosis of early inflammation and early sepsis, and effectively guide the rational use of antibiotics. During acute inflammatory responses such as infection, internal and external trauma, surgery, stress response, brain death, tumor formation, and other situations, the rapid production of IL-6 contributes to host defense, and elevated IL-6 is positively correlated with the severity of the disease. Continuous monitoring of IL-6 levels in serum or plasma can effectively assess the severity of systemic inflammatory response syndrome (SIRS) and the prognosis of sepsis and septic shock. In addition, there are significant differences in IL-6 levels in different inflammatory diseases. For example, the increase in IL-6 levels caused by bacterial infection is significantly higher than that caused by non-bacterial infection. Therefore, accurate detection of IL-6 expression levels in vivo can provide reliable data for understanding the condition, assessing the severity of the condition, and judging the prognosis and efficacy observation.
[0003] Sheep are one of the six domestic animals in traditional animal husbandry and an important livestock breed in social production and life. They play an important role in ensuring the supply of meat in life and increasing the income of farmers and herdsmen. To achieve high-quality development of the sheep farming industry, disease prevention and quality control are crucial. The expression level of IL-6 is closely related to diseases such as inflammation and bacterial infection. Under physiological conditions, the expression level of IL-6 in sheep blood is low and difficult to be accurately quantified. Therefore, providing an IL-6 detection method with high analytical sensitivity has important practical significance and promotion and application value for preventing and monitoring livestock and sheep diseases.
[0004] At present, immunoassays based on the specific and highly sensitive reaction between antigens and antibodies have the advantages of low cost and strong selectivity, and have become the main research direction for protein level detection, such as colloidal gold immunochromatography, latex immunochromatography, radioimmunoassay, enzyme-linked immunosorbent assay or chemiluminescent immunoassay. The key technology lies in the development of antibodies that specifically recognize and bind to IL-6. However, the current lack of IL-6 antibodies with high affinity and specificity has greatly limited its sensitivity and detection efficiency. Summary of the invention
[0005] In view of the problems of low sensitivity of immunoassay due to low antibody affinity and / or low specificity in the prior art, the present invention provides two rabbit-derived antibodies and antibody pairs thereof, which have high recognition specificity for sheep IL-6 protein, good recognition and binding activity, high affinity, and are used for immunoassay of sheep IL-6 with the advantages of high accuracy, high specificity, high sensitivity and good stability. Therefore, the present invention also provides the use of the above-mentioned antibodies and antibody pairs in the preparation of sheep interleukin 6 detection reagents or kits. The present invention is specifically implemented by the following technical solutions:
[0006] The first aspect of the present invention provides an anti-sheep interleukin 6 antibody, selected from a first antibody or a second antibody, wherein: the amino acid sequences of CDR1-3 on the light chain variable region of the first antibody are shown as SEQ ID NOs.3-5, respectively, and the amino acid sequences of CDR1-3 on the heavy chain variable region are shown as SEQ ID NOs.8-10, respectively; the amino acid sequences of CDR1-3 on the light chain variable region of the second antibody are shown as SEQ ID NOs.13-15, respectively, and the amino acid sequences of CDR1-3 on the heavy chain variable region are shown as SEQ ID NOs.18-20, respectively.
[0007] Furthermore, the amino acid sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.7; the amino acid sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown as SEQ ID NO.17.
[0008] Furthermore, the amino acid sequence of the light chain of the first antibody is shown as SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.6; the amino acid sequence of the light chain of the second antibody is shown as SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown as SEQ ID NO.16.
[0009] Furthermore, the first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; the antigen-binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.
[0010] The second aspect of the present invention provides a nucleic acid molecule, a recombinant vector comprising the nucleic acid molecule or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody or the second antibody as described above.
[0011] Furthermore, the nucleotide sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.22, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.24; the nucleotide sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.26, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.28.
[0012] Furthermore, the nucleotide sequence of the light chain of the first antibody is shown as SEQ ID NO.21, and the nucleotide sequence of the heavy chain is shown as SEQ ID NO.23; the nucleotide sequence of the light chain of the second antibody is shown as SEQ ID NO.25, and the nucleotide sequence of the heavy chain is shown as SEQ ID NO.27.
[0013] The third aspect of the present invention provides an anti-sheep interleukin-6 antibody pair, which consists of the first antibody and the second antibody as described above.
[0014] The fourth aspect of the present invention provides the use of the anti-ovine interleukin-6 antibody or antibody pair as described above in the preparation of an ovine interleukin-6 detection reagent or kit.
[0015] Furthermore, the detection reagent or kit comprises a first antibody and a second antibody, wherein the first antibody serves as a capture antibody, and the second antibody modified with a detection label serves as a detection antibody.
[0016] Compared with the prior art, the advantages and positive effects of the present invention are:
[0017] 1. The two rabbit-derived antibodies provided by the present invention can specifically recognize sheep interleukin-6, have a high degree of specificity for sheep interleukin-6 protein, and have good recognition and binding activity and high affinity, providing an antibody raw material with excellent performance for immunodetection of the distribution or expression level of interleukin-6 protein.
[0018] 2. The two antibodies provided by the present invention recognize different antigenic determinants on the surface of sheep interleukin-6 protein, and can be used to develop a double antibody sandwich enzyme-linked immunosorbent assay (ELISA) detection system, providing a feasible and reliable method for accurately, specifically, sensitively, efficiently and stably detecting trace levels of sheep IL-6 protein in serum, cells and tissue samples, and having broad market prospects and good economic and social benefits. BRIEF DESCRIPTION OF THE DRAWINGS
[0019] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.
[0020] Figure 1 The vector map used to construct the rabbit monoclonal antibody expression vector in Example 1 of the present invention, from left to right are the pBR322 vector maps carrying the light chain constant region and the heavy chain constant region;
[0021] Figure 2 This is an affinity curve diagram of the binding between rabbit monoclonal antibody 4C1 and sheep IL-6 in Example 2 of the present invention;
[0022] Figure 3 This is an affinity curve diagram of the binding between rabbit monoclonal antibody 4E2 and goat IL-6 in Example 2 of the present invention;
[0023] Figure 4 The epitope recognition curve of the rabbit monoclonal antibodies 4C1 and 4E2 binding to sheep IL-6 in Example 2 of the present invention;
[0024] Figure 5 The standard curve of the double antibody sandwich ELISA for detecting sheep IL-6 based on rabbit monoclonal antibodies 4C1 and 4E2 established in Example 3 of the present invention;
[0025] Figure 6 This is a graph showing the thermal stability determination results of the double antibody sandwich ELISA method based on rabbit monoclonal antibodies 4C1 and 4E2 established in Example 3 of the present invention;
[0026] Figure 7 This is a graph showing the specificity determination results of the double antibody sandwich ELISA method established based on rabbit monoclonal antibodies 4C1 and 4E2 in Example 3 of the present invention. DETAILED DESCRIPTION
[0027] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.
[0028] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.
[0029] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.
[0030] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.
[0031] The meaning of the terms "including", "comprising", "containing", "having" and the like is non-restrictive, that is, other steps and other ingredients that do not affect the results can be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" is regarded as including the following situations: (i) A, (ii) B and (iii) A and B. The terms "first", "second", etc. are used to distinguish similar objects, and are not necessarily used to describe a specific order or sequence. It should be understood that such usage can be interchangeable under appropriate circumstances.
[0032] The terms "rabbit monoclonal antibody", "monoclonal antibody", "rabbit antibody" and "rabbit monoclonal antibody" and other similar terms have the same meaning and can be used interchangeably. Unless otherwise specified, they all refer to antibodies that specifically bind to sheep interleukin 6. The modifier "rabbit" indicates that the complementary determining region (CDR) of the antibody is derived from a rabbit immunoglobulin sequence. The terms "sheep interleukin 6", "Sheep IL-6" and other similar terms have the same meaning and can be used interchangeably.
[0033] An antibody is an immunoglobulin molecule that can specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of the immunoglobulin molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen-binding activity.
[0034] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, determining the specificity of the antibody and being the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.
[0035] CDRs and FRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, the Kabat numbering system is used to define.
[0036] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.
[0037] A full-length antibody is the most complete antibody molecular structure and has a typical Y-shaped molecular structure. Therefore, in the context of the present invention, "full-length antibody", "complete antibody" and "Y-shaped antibody" have the same meaning and can be used interchangeably.
[0038] Antibody fragments are one or more parts or fragments of a full-length antibody, which substantially retain the same biological function or activity as the full-length form. Specifically, antibody fragments at least include the same CDR region as the full-length antibody, and more preferably have the same variable region, thereby retaining complete antigen recognition and binding sites, and can bind to the same antigen as the full-length antibody, especially to the same epitope. In typical examples, antibody fragments include: Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv, sc(Fv)2, and these antibody fragments can be obtained by conventional techniques in the art.
[0039] (i) Fab: Antigen-binding fragment (Fab) is a monovalent fragment consisting of a complete light chain (variable region and constant region) and a part of the heavy chain (variable region and the first constant region). By proteolytic cleavage of the full-length antibody, fragments such as Fab, F(ab')2, and Fab' can be obtained. For example, under the action of papain, IgG can be degraded into two Fab fragments and one Fc fragment; under the action of pepsin, IgG can be degraded into one F(ab')2 fragment and one pFc' fragment. The F(ab')2 fragment is further reduced to form two Fab' fragments. Since Fab has an antigen-binding region and a part of the constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration as scFv, but also has a more stable structure.
[0040] (ii) F(ab)2: A bivalent fragment consisting of two Fabs linked by a disulfide bridge at the hinge region.
[0041] (iii) Fv: The variable fragment (Fv) is located at the N-terminus of the antibody Fab fragment, contains only the variable region, and is composed of the variable regions of a light chain and a heavy chain. It is a dimer of VH and VL non-covalently bound (VH-VL dimer). The three CDRs of each variable region interact with each other to form an antigen binding site on the surface of the VH-VL dimer, which has the ability to recognize and bind to antigens, although the affinity is lower than that of the intact antibody.
[0042] (iv) (Fv)2: consists of two Fv fragments covalently linked together.
[0043] (v) scFv: Single-chain variable fragment (scFv) is an Fv fragment composed of a single polypeptide chain, which is composed of a heavy chain variable region (VH) and a light chain variable region (VL) connected by a flexible linker (generally composed of 10-25 amino acids), which retains the binding specificity of the original antibody to the antigen. The linker in the present invention is not particularly limited as long as it does not hinder the expression of the antibody variable regions connected to its two ends. Compared with full-length antibodies, scFv has the characteristics of small molecular weight, so it has higher penetration and lower immune side effects.
[0044] (vi) The sc(Fv)2 fragment is composed of two heavy chain variable regions and two light chain variable regions connected via a linker or the like.
[0045] In some embodiments, the full-length sequence of the antibody or antibody fragment of the present invention may include a complementary determining region (CDR) and a framework region (FR) from a rabbit immunoglobulin sequence. In other embodiments, the antibody may include amino acid residues encoded by non-rabbit immunoglobulin sequences, for example, sheep-derived antibodies, chimeric antibodies, etc., to reduce the body's rejection reaction while maintaining the required specificity and affinity. The term "chimeric antibody" refers to a portion of an antibody derived from a specific source or species, while the rest is derived from a different source or species. The term "sheep-derived antibody" is a chimeric antibody of a non-sheep antibody such as a rabbit antibody's CDR region and a sheep FR region. In some cases, the variable region of a non-sheep antibody is combined with a constant region of a sheep antibody, such as a sheep-rabbit chimeric antibody; in other cases, the CDR region of a non-sheep antibody is combined with a FR region and a constant region derived from a sheep antibody sequence, that is, the CDR region of a non-sheep antibody is grafted onto a sheep antibody framework (FR) sequence, and this framework sequence is derived from a single or multiple other sheep antibody variable region framework sequences. In the present invention, the CDR region in the chimeric antibody or goat-derived antibody is derived from a rabbit-derived CDR region.
[0046] The terms "monoclonal antibody" or "single antibody" and the like are used interchangeably and refer to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for a small amount of mutations and / or post-translational modifications (e.g., isomerization, amidation) that may occur naturally. "Monoclonal antibodies" are highly specific and exhibit a single binding specificity and affinity for the same or substantially identical epitopes on an antigen. The modifier "monoclonal" indicates that the antibody is obtained from a substantially homogeneous antibody population and should not be construed as limiting the source or preparation method of the antibody. The antibody can be prepared by a variety of methods, including but not limited to hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.
[0047] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.
[0048] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.
[0049] The embodiment of the present invention provides an anti-sheep interleukin 6 antibody, wherein the antibody is selected from a first antibody or a second antibody, wherein the first antibody and the second antibody both include a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region both include three complementary determining regions (CDRs), respectively named CDR1, CDR2 and CDR3; wherein:
[0050] The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the first antibody are shown in SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively;
[0051] The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the second antibody are shown in SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown in SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, respectively.
[0052] The affinity and specificity of antibodies for potential antigens lie in the spatial conformational complementarity between the complementary determining region (CDR) of the antibody and the antigenic determinant. The two rabbit-derived antibodies of the present invention having the above CDR sequences have the ability to specifically recognize sheep interleukin-6 protein. Through cross-experiments, it was found that both antibodies specifically recognize and bind to sheep interleukin-6 protein only, and have no cross-reaction to proteins of other species. They have high specificity and good binding activity to sheep interleukin-6 protein, with an affinity constant K of 1. D All of them are at the 0.1nM level, with high affinity, providing an antibody raw material with excellent performance for immunodetection of the distribution or expression level of interleukin 6 protein. In addition, the two antibodies provided by the present invention recognize different antigenic determinants on the surface of sheep interleukin 6 protein, and can be used to develop a double antibody sandwich enzyme-linked immunosorbent (ELISA) detection system, which has good detection specificity, high detection sensitivity, excellent anti-interference ability and thermal stability. Taking the first antibody as the capture antibody and the second antibody as the detection antibody as an example, interleukin 6 is quantitatively detected, and the detection limit can be as low as 2.146pg / mL, which provides a feasibility and reliability method for accurately, specifically, sensitively, efficiently and stably detecting trace levels of sheep IL-6 protein in serum, cells and tissue samples, and has broad market prospects and good economic and social benefits.
[0053] Optionally, the light chain variable region and the heavy chain variable region each include 4 framework regions (FRs), and the 4 FRs and 3 CDRs are arranged alternately in sequence to form a variable region. The amino acid sequence of the light chain variable region (VL) of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.7. The amino acid sequence of the light chain variable region (VL) of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region (VH) is shown in SEQ ID NO.17.
[0054] Optionally, the first antibody and the second antibody further include a light chain constant region (CL) and a heavy chain constant region (CH), and each antibody CL and VL constitute a light chain (FL), and CH and VH constitute a heavy chain (FH). The constant region of an antibody can usually be obtained through public inquiries, such as: searching for rabbit IgG gamma C reign to obtain CH through the IMGT online database (www.imgt.org), and searching for rabbit IgG Kappa Creign to obtain CL. Specifically, the amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6. The amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.16.
[0055] Optionally, the first antibody and / or the second antibody is a full-length antibody (having a typical Y-shaped molecular structure) or an antigen binding region of the full-length antibody; the antigen binding region refers to a polypeptide that substantially maintains the same biological function or activity as the full-length form of a rabbit monoclonal antibody. Specifically, the antigen binding region includes the CDR region as described above, and more preferably has the variable region as described above, thereby retaining a complete antigen recognition and binding site, and can bind to the same antigen as the full-length antibody, especially to the same epitope. Optionally, the antigen binding region is selected from at least one of Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv and sc(Fv)2. These antigen binding regions can be obtained by conventional techniques in the art.
[0056] Yet another embodiment of the present invention provides a nucleic acid molecule, a recombinant vector or a host cell comprising the nucleic acid molecule, wherein the nucleic acid molecule encodes the first antibody and / or the second antibody as described above.
[0057] Nucleic acid molecules can be in the form of DNA (such as cDNA or genomic DNA or synthetic DNA) or RNA (such as mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can also be a coding strand or a non-coding strand.
[0058] The sequence of the nucleic acid molecule can be obtained by conventional means such as deduction of codon coding rules based on the amino acid sequence of the antibody. The full-length sequence of the nucleic acid molecule or its fragment can usually be obtained by PCR amplification, recombination or artificial synthesis. The obtained nucleic acid molecule is inserted into an expression vector, then transfected into a host cell, and the transfected host cell is cultured under specific conditions to express the antibody of the present invention.
[0059] Illustratively, the nucleotide sequence of the light chain variable region of the first antibody is shown as SEQ ID NO.22, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.24; the nucleotide sequence of the light chain variable region of the second antibody is shown as SEQ ID NO.26, and the nucleotide sequence of the heavy chain variable region is shown as SEQ ID NO.28.
[0060] Illustratively, the nucleotide sequence of the light chain of the first antibody is shown as SEQ ID NO.21, and the nucleotide sequence of the heavy chain is shown as SEQ ID NO.23; the nucleotide sequence of the light chain of the second antibody is shown as SEQ ID NO.25, and the nucleotide sequence of the heavy chain is shown as SEQ ID NO.27.
[0061] The original vector for constructing the recombinant vector is any conventional vector in the art, as long as it can hold the nucleic acid molecule. Typical vectors include plasmids, viral vectors, bacteriophages, cosmids, and minichromosomes. The vector can be a cloning vector (i.e., used to transfer the nucleic acid molecule to a host and multiply it in a host cell) or an expression vector (i.e., containing the necessary genetic elements to allow the nucleic acid molecule inserted into the vector to be expressed in a host cell). The nucleic acid molecule of the present invention can be inserted into a suitable vector to form a cloning vector or an expression vector carrying the nucleic acid molecule.
[0062] The nucleic acid molecules encoding the antibodies FL and FH of the present invention can be inserted into two vectors, respectively, which can be introduced into the same or different host cells. When FL and FH are expressed in different host cells, each chain can be separated from the host cell expressing it, and the separated FL and FH are mixed and incubated under suitable conditions to form antibodies. In other embodiments, the nucleic acid molecules encoding the antibodies FL and FH of the present invention can also be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding FL and FH can be operably connected to different promoters, or the nucleic acid sequences encoding FL and FH can be operably connected to a single promoter, so that FL and FH can be expressed by the same promoter. The choice of expression vector / promoter depends on the type of host cell used to produce the antibody.
[0063] In the present invention, the recombinant vector is transfected or transformed into the host cell using conventional techniques. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA are harvested after the exponential growth phase and treated with CaCl2 or MgCl2; or by microinjection, electroporation or liposome packaging. When the host is a eukaryotic organism, the following DNA transfection methods can be selected: calcium phosphate coprecipitation, microinjection, electroporation, liposome packaging, etc.
[0064] The host cell can be a prokaryotic or eukaryotic cell. Representative examples include: Escherichia coli, Streptomyces, Salmonella typhimurium, yeast, Drosophila S2 or Sf9 cells, mammalian CHO, COS7, 293 series cells, etc. After obtaining the host cell transfected or transformed with the recombinant vector as described above, the antibody can be expressed by culturing under suitable conditions, and then separated to obtain purified antibody.
[0065] In a preferred embodiment, the recombinant vector is a mammalian expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).
[0066] Another embodiment of the present invention provides an anti-sheep interleukin-6 antibody pair, which consists of the first antibody and the second antibody as described above.
[0067] The first antibody and the second antibody provided by the present invention bind to different epitopes on the surface of sheep IL-6, and are used to develop a double antibody sandwich enzyme-linked immunosorbent assay system for sheep IL-6 protein, which has the advantages of high specificity, high sensitivity, good reliability, etc.
[0068] Another embodiment of the present invention provides the use of the anti-ovine interleukin 6 antibody or antibody pair described above in the preparation of an ovine interleukin 6 detection reagent or kit.
[0069] The advantages of using the anti-sheep interleukin 6 antibody or antibody pair in preparing a sheep interleukin 6 detection reagent or kit are the same as the advantages of the anti-sheep interleukin 6 antibody or antibody pair over the prior art as described above, and will not be repeated here.
[0070] Based on the same inventive concept as above, an embodiment of the present invention further provides a detection reagent or kit for detecting ovine interleukin 6, wherein the detection reagent or kit comprises the first antibody and / or the second antibody as described above.
[0071] It should be emphasized that the first antibody and the second antibody can be used separately, together, or in pairs. When detecting, if used separately or together, the first antibody and / or the second antibody is used as a primary antibody or a capture antibody, the sample to be tested is contacted with the first antibody and / or the second antibody, and then the antibody is detected. In some embodiments, the first antibody and / or the second antibody can be coupled to a detection label, and the qualitative or quantitative detection of IL-6 is achieved by analyzing the changes in the identifiable signal generated by the detection label. In other embodiments, the first antibody and / or the second antibody against sheep IL-6 are not labeled (the first antibody and / or the second antibody is used as a primary antibody or a capture antibody), and the detection label is coupled to a secondary antibody that can bind to the primary antibody (the secondary antibody is used as a detection antibody) or other molecules. For example, if the anti-sheep IL-6 antibody is a rabbit IgG antibody, then the secondary antibody can be an anti-rabbit IgG antibody, thereby generating a change in the identifiable signal by coupling the secondary antibody of the detection label. When used in pairs, one of the first antibody and the second antibody is used as a primary antibody or a capture antibody, and the other is used as a secondary antibody or a detection antibody.
[0072] The above-mentioned detection method adopts common immunological methods, including but not limited to: enzyme immunoassay (EIA), enzyme-linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), immunohistochemistry (IHC), immunofluorescence (IF), immunoblotting (WB), flow cytometry (FC), etc. The detection objects include recombinantly expressed IL-6, naturally secreted or expressed IL-6 protein. The detection samples include but are not limited to IL-6 protein in serum, plasma, urine, cell culture fluid, etc.
[0073] Preferably, the detection reagent or kit comprises a first antibody and a second antibody, wherein the first antibody serves as a capture antibody (or primary antibody), the second antibody serves as a detection antibody (or secondary antibody), and the second antibody is modified with a detection label.
[0074] The above-mentioned detection labels for generating identifiable signal changes include, but are not limited to: biotin, fluorescent dyes (such as umbelliferone, fluorescein, fluorescein isothiocyanate, rhodamine, dichlorotriazinylamine fluorescein, dansyl chloride), fluorescent proteins (such as allophycocyanin, phycoerythrin, PerCP and phycocyanin), enzymes (such as alkaline phosphatase, acid phosphatase, β-galactosidase, glucose oxidase, horseradish peroxidase, acetylcholinesterase, avidin), colloidal gold, colored magnetic beads, latex particles, radionuclides, detection antibodies or combinations thereof.
[0075] In a preferred embodiment, the detection label is biotin.
[0076] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.
[0077] Example 1 Preparation of rabbit monoclonal antibody against sheep interleukin-6
[0078] This embodiment uses recombinant sheep interleukin 6 protein (purchased from Abcam, item number ab235819) as an immunogen, immunizes New Zealand white rabbits, separates single antigen-specific B lymphocytes from spleen cells and cultures them, extracts the gene amplification products of the heavy chain variable region (VH) and light chain variable region (VL) corresponding to the antibody by specific primers, and further constructs them into expression vectors containing heavy chain constant region and light chain constant region, and transfects host cells, and culture host cells to obtain supernatant containing rabbit monoclonal antibodies, and purifies them to obtain candidate rabbit monoclonal antibodies. Afterwards, they are screened by affinity testing and antigen epitope identification to obtain rabbit monoclonal antibodies 4C1 and 4E2. The screened antibodies are sequenced, and the sequencing work is completed by Jin Kairui Biotechnology Co., Ltd. The amino acid (AA) and nucleotide (DNA) sequences of antibodies 4C1 and 4E2 are shown in Tables 1-2, respectively. For the convenience of description below, the light chain complementary determining regions CDR1, CDR2 and CDR3 are represented by LCDR1, LCDR2 and LCDR3, respectively, and the heavy chain complementary determining regions CDR1, CDR2 and CDR3 are represented by HCDR1, HCDR2 and HCDR3, respectively.
[0079] Table 1 Sequence information of rabbit monoclonal antibody 4C1 in this example
[0080]
[0081] Table 2 Sequence information of rabbit monoclonal antibody 4E2 in this example
[0082]
[0083]
[0084] The preparation method of rabbit antibody 4C1 and antibody 4E2 specifically includes the following steps:
[0085] 1. Animal immunization: 2 New Zealand rabbits were immunized with commercialized sheep interleukin-6 protein; 200 μg of each rabbit was immunized, and before the first immunization, the immunogen was mixed with an equal amount of complete Freund's adjuvant to prepare an emulsifier, which was injected subcutaneously at multiple points on the rabbit's abdomen and back; after the first immunization, 100 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant to prepare an emulsifier every 3 weeks, and injected subcutaneously at multiple points on the rabbit's abdomen and back, and boosted immunization was performed twice; after three immunizations, rabbit serum samples were collected, and the titer against sheep interleukin-6 was determined by ELISA method, and rabbits with high serum titers were selected and boosted immunization was performed once with 200 μg of the immunogen injected subcutaneously at multiple points, and the animals were sacrificed three days later to obtain the spleen.
[0086] 2. Isolate B lymphocytes from the spleen and sort B lymphocytes: Use conventional methods to isolate B lymphocytes from the spleen, and sort out antigen-specific B lymphocytes. For related methods, please refer to the patent "Method for efficiently separating single antigen-specific B lymphocytes from spleen cells (publication number: CN110016462A, publication date: 2019-07-16)" and the patent "A B lymphocyte in vitro culture system and application (publication number: CN111518765A, publication date: 2020-08-11)".
[0087] 3. Cloning of the gene encoding rabbit monoclonal antibody: The cultured B lymphocyte supernatant was used to identify positive clones by antigen-coated ELISA. The positive clone cells were collected and lysed and then analyzed by Quick-RNA TMRNA was extracted according to the instructions of MicroPrep kit (purchased from ZYMO, catalog number R1051) and reverse transcribed into cDNA. Using the above cDNA as a template, the naturally paired rabbit monoclonal antibody light chain variable region (VL) and heavy chain variable region (VH) were amplified from the cDNA of the corresponding positive clone by PCR and sequenced. The PCR reaction system included: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2×Gloria HiFi (from ABclonal, catalog number RK20717) and 6.5 μL H2O; the PCR amplification program included: 98℃ pre-denaturation for 30 s, followed by 40 cycles of 98℃ for 10 s, 64℃ for 30 s, and 72℃ for 30 s, and finally kept at 72℃ for 5 min. The obtained reaction solution was stored at 4℃. The primer sequences (5'-3') for amplifying VL and VH genes are as follows, where F and R represent forward primers and reverse primers, respectively:
[0088] VL-F: tgaattcgagctcggtacccatggacacgagggcccccac (see SEQ ID NO. 29);
[0089] VL-R: cacacacgatggtgactgttccagttgccacctgatcag (see SEQ ID NO. 30);
[0090] VH-F: tgaattcgagctcggtacccatggagactgggctgcgctg (see SEQ ID NO. 31);
[0091] VH-R: gtagcctttgaccaggcagcccagggtcaccgtggagctg (see SEQ ID NO. 32).
[0092] 4. Production and purification of rabbit monoclonal antibodies: In order to mass-produce antibodies against sheep IL-6, the mammalian expression vector pBR322 carrying the light chain constant region (CL) and heavy chain constant region (CH) genes was linearized with XbaI and NheI restriction endonucleases, respectively. The VL and VH genes containing the signal peptides amplified by the above PCR were purified and then constructed upstream of the CL and CH genes of the expression vectors by homologous recombination to obtain light chain (FL) and heavy chain (FH) gene expression vectors. The vector construction was successfully verified by sequencing. The expression map of the vector used is shown in Figure 1, pBR322 origin and f1 origin are replication promoters, Ampcillin is a resistance gene, CMV promoter is a transcription promoter, SV40 PA terminator is a tailing signal, Light chain constant is the nucleic acid sequence of the light chain constant region (left), Heavy chain constant is the nucleic acid sequence of the heavy chain constant region (right). CL and CH genes were obtained by searching the IMGT online database (www.imgt.org) to obtain CH from rabbit IgG gamma C reign, and CL from rabbit IgG Kappa C reign.
[0093] The signal peptide of this embodiment adopts the antibody expression signal peptide sequence commonly used in the art, such as the patent "Rabbit monoclonal antibody against human interferon α2 and its application (publication number: CN116063487A, publication date: 2023-05-05)" and the patent "High-affinity Human IL-5 rabbit monoclonal antibody and its application (publication number: CN115819578A, publication date: 2023-03-21)" The light chain variable region upstream has a signal peptide "MDTRAPTQLLGLLLLWLPGATF" or "MDTRAPTQLLGLLLLWLPGARC", and the heavy chain variable region upstream has a signal peptide "METGLRWLLLVAVLKGVQC".
[0094] The expression vectors containing the light chain (FL) gene and the heavy chain (FH) gene verified by sequencing were transfected into 293F cells together. After transfection, the cells were cultured for 72-96 hours to obtain the culture supernatant containing the recombinant rabbit monoclonal antibody that recognizes sheep IL-6. The target antibody was purified from the culture supernatant using protein A affinity gel resin (purchased from Tiandi Renhe, catalog number SA023100). Using 12% SDS-PAGE gel electrophoresis for detection, the concentration of antibody 4C1 was 2.3 mg / mL, and the concentration of antibody 4E2 was 2.44 mg / mL, and the purity was greater than 95%. The purified antibodies were divided and stored at -20°C for later use.
[0095] Example 2 Performance test of rabbit monoclonal antibodies 4C1 and 4E2 in recognizing IL-6 antigen
[0096] 1) The affinity of antibodies 4C1 and 4E2 to sheep IL-6 protein was measured using the Probe Life Gator biomolecular interaction analyzer, with the concentration of antibody 4C1 being 1 μg / mL and the concentration of antibody 4E2 being 4 μg / mL; the antibodies were fixed on the protein A probe, and then the antibody 4C1 and antibody 4E2 were bound to IL-6 protein at two concentrations of 70 nM and 150 nM, respectively, to obtain affinity curves. The affinity curves of antibodies 4C1 and 4E2 binding to sheep IL-6 are shown in Figure 2-3 , where the ordinate represents the change in the thickness of the conjugate after the probe binds to the antibody and protein, the abscissa represents the binding time, the dark gray curve is the real-time binding value curve, and the light gray curve is the fitted average curve. The affinity constants calculated by curve fitting are shown in Table 3, where the dissociation coefficient K off The constant used to characterize the dissociation rate between antibody and antigen, the binding coefficient K on A constant used to characterize how quickly an antibody binds to its target, the affinity constant K D K off / K on The ratio of , represents the equilibrium dissociation constant between the antibody and its antigen. It can be seen that the affinity constants K of antibodies 4C1 and 4E2 and sheep IL-6 protein are D All were at the 0.1nM level, confirming that the antibodies had high affinity and good specificity.
[0097] Table 3 Affinity-related parameter determination results of rabbit monoclonal antibodies
[0098] Antibody <![CDATA[K off (1 / s)]]> <![CDATA[K on (1 / Ms)]]> <![CDATA[K D (M)]]> 4C1 <![CDATA[1.15×10 -4 ]]> <![CDATA[3.64×10 5 ]]> <![CDATA[3.17×10 -10 ]]> 4E2 <![CDATA[7.96×10 -5 ]]> <![CDATA[6.08×10 5 ]]> <![CDATA[1.31×10 -10 ]]>
[0099] 2) Identification of antigen recognition epitopes: The epitopes of sheep IL-6 protein recognized by antibodies 4C1 and 4E2 were identified using the Probe Life Gator Biomolecular Interaction Analyzer, with the antibody and antigen concentrations both at 3 μg / mL. By analyzing the pairing data between the two antibodies, it was determined whether the epitope determinants they recognized were the same. Figure 4 The figure shows the antigen epitope recognition of sheep IL-6 by 4C1 and 4E2, where the ordinate represents the change in the thickness of the conjugate after the probe binds to the antibody and protein, and the abscissa represents the binding time of the antibody and the antigen protein. It can be seen that after the antibody 4C1 binds to sheep interleukin 6, the antibody 4E2 is still able to bind, which is reflected in the further rise of the curve, indicating that the concentration and thickness of the antibody bound to the probe are further enhanced, proving that the rabbit monoclonal antibodies 4C1 and 4E2 bind to different parts of the surface of the sheep interleukin 6 protein, and the binding sites do not interfere with each other. Therefore, the two can be used as paired antibodies for double antibody sandwich enzyme-linked immunosorbent assay.
[0100] Example 3 Sensitivity test of double antibody sandwich ELISA system based on antibodies 4C1 and 4E2
[0101] A double antibody sandwich enzyme-linked immunosorbent assay (ELISA) system was established using 4C1 as the capture antibody and 4E2 as the detection antibody. The steps are as follows: 1) Coating the capture antibody 4C1: dilute the antibody 4C1 to 0.5 μg / mL with 1×PBS, mix it with a vortexer, add it to a 96-well microplate at 100 μL / well, cover it with a cover film, and incubate it in a 4°C refrigerator for 16-20 hours; 2) Washing the plate: after the incubation is completed, discard the liquid in the well, wash the plate once with 1×PBST, add 350 μL of the sample, let it stand for 40 seconds, then discard the liquid in the well, and pat the liquid in the well dry on a flat paper; 3) Blocking: Add E013 blocking solution (1×PBS containing 2% BSA, 5% sucrose, 0.05% Tween and 0.1% proclin 300, pH 5.0) to the plate. 7.2) Add 200 μL / well to the plate wells, cover with a cover film, and block at 37°C for 2 hours. After blocking, discard the blocking solution, pat the ELISA plate dry, place it in a 37°C oven to dry for 0.5-2 hours, and take it out for use; 4) Add antigen IL-6 protein: dilute the sheep IL-6 protein with E013 blocking solution in a gradient manner (dilution concentration: 1000, 500, 250, 125, 62.5, 31.25, 15.635 and 0pg / mL), then add different concentrations to the ELISA plate at 100 μL / well in turn, cover with a cover film, and incubate at 37°C for 2 hours; 5) Wash the plate: After incubation, discard the solution in the wells. 6) Add detection antibody 4E2: dilute the rabbit monoclonal antibody 4E2 (4E2-biotin) labeled with biotin to 0.04 μg / mL, add 100 μL / well to the ELISA plate, cover with a cover film, and incubate at 37°C for 1 hour; wherein, the 4E2-biotin treatment method includes: preparing the antibody 4E2 into a 1 mg / mL solution, preparing NHS-LC-biotin into a 60 mg / mL solution with DMSO; taking 200 μL of the 1 mg / mL antibody 4E2 solution, adding 10 μL of the 60 mg / mL NHS-LC-biotin solution; mixing and placing at room temperature for 30 minutes, adding 50 μg of 500 mM Tris solution (pH 9.0) to stop the reaction; finally, adding a large amount of pH 7.4) 1×PBS buffer, centrifuged with a centrifugal column with an exclusion limit of 30KD to remove excess biotin molecules and balance the buffer system; 7) Washing: After incubation, discard the liquid in the wells, wash the plate three times with 1×PBST, add 300μL of sample, let it stand for 40s, then discard the liquid in the wells, and pat the liquid in the wells dry on a flat paper; 8) Add SA-HRP: dilute 100×SA-HRP (horseradish peroxidase labeled streptavidin, purchased from Wuhan Sanying Biotechnology Co., Ltd., product number SA00001-0) concentrate 100 times, and add 100μL / well in sequence In the ELISA plate, cover with a cover film and incubate at 37°C for 0.5h; 9) Washing: After the incubation is completed, discard the liquid in the well, wash the plate three times with 1×PBST, add 300μL of sample, let it stand for 40s, then discard the liquid in the well, and pat the liquid in the well dry on a flat paper; 10) Add TMB colorimetric solution: Add 3,3',5,5'-tetramethylbenzidine (TMB) colorimetric solution to the ELISA plate at 100μL / well, cover with a cover film, and incubate at 37°C for 15min; 11) Reading: After the incubation is completed, take out the ELISA plate, add 50μL of stop solution (1mol / L hydrochloric acid) to each well, and immediately read with an ELISA reader. With the concentration of sheep interleukin 6 protein as the horizontal axis, the correction value of the absorbance value is Y1 (Y1=OD. 450nm -OD 630nm ) as the ordinate, and the four-parameter fitting of the Logistic curve was used to establish the standard curve. Figure 5 , the curve equation is: y = 7.71018 / [1+(x / 2636.05835)^ -1.03201 ]+0.07514(R 2 =0.99999). The detection sensitivity was calculated by the standard curve to be 2.146 pg / mL (i.e., the detection limit can be as low as 2.146 pg / mL). The results are shown in Table 4, which proves that the antibody pair has the advantages of high sensitivity and good reliability.
[0102] Table 4 Sensitivity test data of double antibody sandwich ELISA system based on antibodies 4C1 and 4E2
[0103]
[0104] Example 4 Thermal stability test of double antibody sandwich ELISA system based on antibodies 4C1 and 4E2
[0105] The detection system formed by the ELISA plate coated with the capture antibody 4C1, the freeze-dried sheep interleukin-6 protein, and the 100× concentrated detection antibody 4E2 was sealed and stored at -20°C and 37°C for 7 days, and then taken out and tested according to the double antibody sandwich ELISA established in Example 3. The standard curves obtained under different storage temperatures are shown in FIG. Figure 6The results showed that after storage at 37°C for 7 days, the coefficient of variation of the stability of the antibody pair was 3.71%, which was much less than 15%, and the stability was judged to be qualified, indicating that the antibody pair formed by antibodies 4C1 and 4E29 had better stability.
[0106] Example 5 Specificity test of double antibody sandwich ELISA system based on antibodies 4C1 and 4E2
[0107] Human IL-6 (purchased from RD, item number 840115), mouse IL-6 (purchased from RD, item number 840173) and rat IL-6 (purchased from RD, item number 840236) similar to sheep IL-6 were used as antigens, and the concentration of the standard protein was 1000 pg / mL. The cross-reaction test was performed according to the double antibody sandwich ELISA established in Example 3. The results are shown in Figure 7 The results showed that antibodies 4C1 and 4E2 only bind to sheep interleukin-6 and do not produce any cross-reactions with other similar proteins; this confirmed that antibodies 4C1 and 4E2 are highly specific to sheep IL-6 protein.
[0108] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.
Claims
1. An anti-sheep interleukin-6 antibody, characterized in that Selected from the first antibody or the second antibody, wherein: The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the first antibody are shown in SEQ ID NO.3, SEQ ID NO.4 and SEQ ID NO.5, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively; The amino acid sequences of CDR1, CDR2 and CDR3 in the light chain variable region of the second antibody are shown as SEQ ID NO.13, SEQ ID NO.14 and SEQ ID NO.15, respectively, and the amino acid sequences of CDR1, CDR2 and CDR3 in the heavy chain variable region are shown as SEQ ID NO.18, SEQ ID NO.19 and SEQ ID NO.20, respectively.
2. The anti-sheep interleukin-6 antibody according to claim 1, characterized in that The amino acid sequence of the light chain variable region of the first antibody is shown in SEQ ID NO.2, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.7; The amino acid sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.12, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.
17.
3. The anti-sheep interleukin-6 antibody according to claim 2, characterized in that The amino acid sequence of the light chain of the first antibody is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.6; The amino acid sequence of the light chain of the second antibody is shown in SEQ ID NO.11, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.
16.
4. The anti-sheep interleukin-6 antibody according to claim 1, characterized in that The first antibody and / or the second antibody is a full-length antibody or an antigen-binding region of the full-length antibody; The antigen binding region is selected from Fab, F(ab)2, Fab', F(ab')2, Fv, (Fv)2, scFv or sc(Fv)2.
5. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the first antibody or the second antibody according to any one of claims 1 to 4.
6. The nucleic acid molecule according to claim 5, characterized in that The nucleotide sequence of the light chain variable region of the first antibody is shown in SEQ ID NO.22, and the nucleotide sequence of the heavy chain variable region is shown in SEQ ID NO.24; The nucleotide sequence of the light chain variable region of the second antibody is shown in SEQ ID NO.26, and the nucleotide sequence of the heavy chain variable region is shown in SEQ ID NO.
28.
7. The nucleic acid molecule according to claim 6, characterized in that The nucleotide sequence of the light chain of the first antibody is shown in SEQ ID NO.21, and the nucleotide sequence of the heavy chain is shown in SEQ ID NO.23; The nucleotide sequence of the light chain of the second antibody is shown in SEQ ID NO.25, and the nucleotide sequence of the heavy chain is shown in SEQ ID NO.
27.
8. An anti-sheep interleukin-6 antibody pair, characterized in that: The method comprises the first antibody and the second antibody as described in any one of claims 1 to 4.
9. Use of the anti-ovine interleukin 6 antibody according to any one of claims 1 to 4 or the anti-ovine interleukin 6 antibody pair according to claim 8 in the preparation of an ovine interleukin 6 detection reagent or kit.
10. Use of the anti-sheep interleukin 6 antibody or anti-sheep interleukin 6 antibody pair according to claim 9 in the preparation of a sheep interleukin 6 detection reagent or kit, characterized in that: The detection reagent or kit comprises a first antibody and a second antibody, wherein the first antibody serves as a capture antibody, and the second antibody modified with a detection label serves as a detection antibody.
